This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nicolau, D. P.
Right arrow Articles by Quintiliani, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nicolau, D. P.
Right arrow Articles by Quintiliani, R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, Mar 1995, 650-655, Vol 39, No. 3
Copyright © 1995 by the American Society for Microbiology. All rights reserved.

Experience with a once-daily aminoglycoside program administered to 2,184 adult patients

DP Nicolau, CD Freeman, PP Belliveau, CH Nightingale, JW Ross and R Quintiliani
Department of Pharmacy, Hartford Hospital, Connecticut 06102, USA.

Once-daily aminoglycoside (ODA) regimens have been instituted to maximize bacterial killing by optimizing the peak concentration/MIC ratio and to reduce the potential for toxicity. We initiated an ODA program at our institution that utilizes a fixed 7-mg/kg intravenous dose with a drug administration interval based on estimated creatinine clearance: > or = 60 ml/min every 24 h (q24h), 59 to 40 ml/min q36h, and 39 to 20 ml/min q48h. Subsequent interval adjustments are made by using a single concentration in serum and a nomogram designed for monitoring of ODA therapy. Since initiation of the program, 2,184 patients have received this ODA regimen. The median dose was 450 (range, 200 to 925) mg, while the median length of therapy was 3 (range, 1 to 26) days. The median age of the population was 46 (range, 13 to 97) years. Gentamicin accounted for 94% of the aminoglycoside use, and the majority (77%) of patients received the drug q24h. The 36- , 48-, and > 48-h intervals were used for 15, 6, and 2% of this population, respectively. Three patients exhibited clinically apparent ototoxicity. Twenty-seven patients (1.2%) developed nephrotoxicity (the Hartford Hospital historical rate is approximately 3 to 5%) after a median of 7 (range, 3 to 19) days of therapy. On the basis of a prospective evaluation of 58 patients and follow-up of additional patients via clinician reports, we have noted no apparent alterations in clinical response with our ODA program. This ODA program appears to be clinically effective, reduces the incidence of nephrotoxicity, and provides a cost-effective method for administration of aminoglycosides by reducing ancillary service time and serum aminoglycoside determinations.


This article has been cited by other articles:

  • Selby, N. M., Shaw, S., Woodier, N., Fluck, R. J., Kolhe, N. V. (2009). Gentamicin-associated acute kidney injury. QJM 102: 873-880 [Abstract] [Full Text]  
  • Lovering, A. M., Reeves, D. S. (2009). Potentially dangerous misuse of the Hartford once-daily nomogram for gentamicin. J Antimicrob Chemother 64: 1117-1118 [Full Text]  
  • Snead, J. L., O'Hare, T., Adrian, L. T., Eide, C. A., Lange, T., Druker, B. J., Deininger, M. W. (2009). Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. Blood 114: 3459-3463 [Abstract] [Full Text]  
  • Endorsed by the European Society of Clinical Micro, , Authors/Task Force Members, , Habib, G., Hoen, B., Tornos, P., Thuny, F., Prendergast, B., Vilacosta, I., Moreillon, P., de Jesus Antunes, M., Thilen, U., Lekakis, J., Lengyel, M., Muller, L., Naber, C. K., Nihoyannopoulos, P., Moritz, A., Zamorano, J. L., ESC Committee for Practice Guidelines (CPG), , Vahanian, A., Auricchio, A., Bax, J., Ceconi, C., Dean, V., Filippatos, G., Funck-Brentano, C., Hobbs, R., Kearney, P., McDonagh, T., McGregor, K., Popescu, B. A., Reiner, Z., Sechtem, U., Sirnes, P. A., Tendera, M., Vardas, P., Widimsky, P., Document Reviewers, , Vahanian, A., Aguilar, R., Bongiorni, M. G., Borger, M., Butchart, E., Danchin, N., Delahaye, F., Erbel, R., Franzen, D., Gould, K., Hall, R., Hassager, C., Kjeldsen, K., McManus, R., Miro, J. M., Mokracek, A., Rosenhek, R., San Roman Calvar, J. A., Seferovic, P., Selton-Suty, C., Uva, M. S., Trinchero, R., van Camp, G. (2009). Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): The Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Eur Heart J 30: 2369-2413 [Full Text]  
  • Gupta, R., Wargo, K. A. (2008). An Update on the Management of Nosocomial Pneumonia. Journal of Pharmacy Practice 21: 380-389 [Abstract]  
  • Rose, W. E., Leonard, S. N., Rybak, M. J. (2008). Evaluation of Daptomycin Pharmacodynamics and Resistance at Various Dosage Regimens against Staphylococcus aureus Isolates with Reduced Susceptibilities to Daptomycin in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations. Antimicrob. Agents Chemother. 52: 3061-3067 [Abstract] [Full Text]  
  • Sowinski, K. M., Magner, S. J., Lucksiri, A., Scott, M. K., Hamburger, R. J., Mueller, B. A. (2008). Influence of Hemodialysis on Gentamicin Pharmacokinetics, Removal During Hemodialysis, and Recommended Dosing. CJASN 3: 355-361 [Abstract] [Full Text]  
  • Freundlich, M., Thomsen, R. W., Pedersen, L., West, H., Schonheyder, H. C. (2007). Aminoglycoside treatment and mortality after bacteraemia in patients given appropriate empirical therapy: a Danish hospital-based cohort study. J Antimicrob Chemother 60: 1115-1123 [Abstract] [Full Text]  
  • Seaton, C., Ignas, J., Muchohi, S., Kokwaro, G., Maitland, K., Thomson, A. H. (2007). Population pharmacokinetics of a single daily intramuscular dose of gentamicin in children with severe malnutrition. J Antimicrob Chemother 59: 681-689 [Abstract] [Full Text]  
  • Tanigawara, Y., Sato, R., Morita, K., Kaku, M., Aikawa, N., Shimizu, K. (2006). Population Pharmacokinetics of Arbekacin in Patients Infected with Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 50: 3754-3762 [Abstract] [Full Text]  
  • Sato, R., Tanigawara, Y., Kaku, M., Aikawa, N., Shimizu, K. (2006). Pharmacokinetic-Pharmacodynamic Relationship of Arbekacin for Treatment of Patients Infected with Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 50: 3763-3769 [Abstract] [Full Text]  
  • Burkhardt, O., Lehmann, C., Madabushi, R., Kumar, V., Derendorf, H., Welte, T. (2006). Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?. J Antimicrob Chemother 58: 822-829 [Abstract] [Full Text]  
  • Scheetz, M. H., Hurt, K. M., Noskin, G. A., Oliphant, C. M. (2006). Applying antimicrobial pharmacodynamics to resistant gram-negative pathogens.. Am J Health Syst Pharm 63: 1346-1360 [Abstract] [Full Text]  
  • Schafer, J. A., Hovde, L. B., Rotschafer, J. C. (2006). Consistent rates of kill of Staphylococcus aureus by gentamicin over a 6-fold clinical concentration range in an in vitro pharmacodynamic model (IVPDM). J Antimicrob Chemother 58: 108-111 [Abstract] [Full Text]  
  • Lorente, L., Lorenzo, L., Martin, M. M, Jimenez, A., Mora, M. L (2006). Meropenem by Continuous Versus Intermittent Infusion in Ventilator-Associated Pneumonia due to Gram-Negative Bacilli. The Annals of Pharmacotherapy 40: 219-223 [Abstract] [Full Text]  
  • Rogers, M. S., Cullen, M. M., Boxall, E. M., Chadwick, P. R. (2005). Improved compliance with a gentamicin prescribing policy after introduction of a monitoring form. J Antimicrob Chemother 56: 566-568 [Abstract] [Full Text]  
  • Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G. Jr, Bolger, A. F., Levison, M. E., Ferrieri, P., Gerber, M. A., Tani, L. Y., Gewitz, M. H., Tong, D. C., Steckelberg, J. M., Baltimore, R. S., Shulman, S. T., Burns, J. C., Falace, D. A., Newburger, J. W., Pallasch, T. J., Takahashi, M., Taubert, K. A. (2005). Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Diseases Society of America. Circulation 111: e394-e434 [Abstract] [Full Text]  
  • Murphy, J. E. (2005). Prediction of gentamicin peak and trough concentrations from six extended-interval dosing protocols for neonates. Am J Health Syst Pharm 62: 823-827 [Abstract] [Full Text]  
  • Lanao, J. M., Calvo, M. V., Mesa, J. A., Martin-Suarez, A., Carbajosa, M. T., Miguelez, F., Dominguez-Gil, A. (2004). Pharmacokinetic basis for the use of extended interval dosage regimens of gentamicin in neonates. J Antimicrob Chemother 54: 193-198 [Abstract] [Full Text]  
  • Kim, M.-J., Bertino, J. S. Jr., Erb, T. A., Jenkins, P. L., Nafziger, A. N. (2004). Application of Bayes Theorem to Aminoglycoside-Associated Nephrotoxicity: Comparison of Extended-Interval Dosing, Individualized Pharmacokinetic Monitoring, and Multiple-Daily Dosing. J Clin Pharmacol 44: 696-707 [Abstract] [Full Text]  
  • Sung, L., Dupuis, L. L., Bliss, B., Taddio, A., Abdolell, M., Allen, U., Rolland, M., Tong, A., Taylor, T., Doyle, J. (2003). Randomized Controlled Trial of Once- Versus Thrice-Daily Tobramycin in Febrile Neutropenic Children Undergoing Stem Cell Transplantation. JNCI J Natl Cancer Inst 95: 1869-1877 [Abstract] [Full Text]  
  • Smith, C. (2003). Pharmacokinetic/Pharmacodynamic Considerations in Community-Acquired Lower Respiratory Tract Infections. Journal of Pharmacy Practice 16: 313-323 [Abstract]  
  • Kuti, J. L., Dandekar, P. K., Nightingale, C. H., Nicolau, D. P. (2003). Use of Monte Carlo Simulation to Design an Optimized Pharmacodynamic Dosing Strategy for Meropenem. J Clin Pharmacol 43: 1116-1123 [Abstract] [Full Text]  
  • Dotan, Z. A., Hana, R., Simon, D., Geva, D., Pfeffermann, R. A., Ezri, T. (2003). The Effect of Vecuronium Is Enhanced by a Large Rather than a Modest Dose of Gentamicin as Compared with No Preoperative Gentamicin. Anesth. Analg. 96: 750-754 [Abstract] [Full Text]  
  • Young, T. E. (2002). Aminoglycoside Therapy in Neonates: With Particular Reference to Gentamicin. NeoReviews 3: e243-248 [Full Text]  
  • Bonapace, C. R., Friedrich, L. V., Bosso, J. A., White, R. L. (2002). Determination of Antibiotic Effect in an In Vitro Pharmacodynamic Model: Comparison with an Established Animal Model of Infection. Antimicrob. Agents Chemother. 46: 3574-3579 [Abstract] [Full Text]  
  • Aminimanizani, A., Beringer, P. M., Kang, J., Tsang, L., Jelliffe, R. W., Shapiro, B. J. (2002). Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. J Antimicrob Chemother 50: 553-559 [Abstract] [Full Text]  
  • Fish, D. N. (2002). Extended-Interval Dosing of Aminoglycoside Antibiotics in Critically Ill Patients. Journal of Pharmacy Practice 15: 85-95 [Abstract]  
  • Whitehead, A., Conway, S.P., Etherington, C., Caldwell, N.A., Setchfield, N., Bogle, S. (2002). Once-daily tobramycin in the treatment of adult patients with cystic fibrosis. Eur Respir J 19: 303-309 [Abstract] [Full Text]  
  • Isoherranen, N., Lavy, E., Soback, S. (2000). Pharmacokinetics of Gentamicin C1, C1a, and C2 in Beagles after a Single Intravenous Dose. Antimicrob. Agents Chemother. 44: 1443-1447 [Abstract] [Full Text]  
  • Mason, E. O. Jr, Lamberth, L. B., Kershaw, N. L., Prosser, B. L. T., Zoe, A., Ambrose, P. G. (2000). Streptococcus pneumoniae in the USA: in vitro susceptibility and pharmacodynamic analysis. J Antimicrob Chemother 45: 623-631 [Abstract] [Full Text]  
  • Bakri, F. E., Pallett, A., Smith, A. G., Duncombe, A. S. (2000). Once-daily versus multiple-daily gentamicin in empirical antibiotic therapy of febrile neutropenia following intensive chemotherapy. J Antimicrob Chemother 45: 383-386 [Abstract] [Full Text]  
  • Buabeng, K. O., Mackenzie, A. R., Laing, R. B. S., Cook, I., Jappy, B., Gould, I. M. (1999). Assessment of the efficacy, safety and quality of gentamicin use in Aberdeen Royal Infirmary. J Antimicrob Chemother 44: 843-845 [Abstract] [Full Text]  
  • Rybak, M. J., Abate, B. J., Kang, S. L., Ruffing, M. J., Lerner, S. A., Drusano, G. L. (1999). Prospective Evaluation of the Effect of an Aminoglycoside Dosing Regimen on Rates of Observed Nephrotoxicity and Ototoxicity. Antimicrob. Agents Chemother. 43: 1549-1555 [Abstract] [Full Text]  
  • Lundergan, F. S., Kim, E. H., Cohen, R. S. (1999). Once-daily Gentamicin Dosing in Newborn Infants. Pediatrics 103: 1228-1234 [Abstract] [Full Text]  
  • Mingeot-Leclercq, M.-P., Tulkens, P. M. (1999). Aminoglycosides: Nephrotoxicity. Antimicrob. Agents Chemother. 43: 1003-1012 [Full Text]  
  • Tomlinson, R. J, Ronghe, M., Goodbourne, C., Price, C., Lilleyman, J. S, Das, S., Saha, V. (1999). Once daily ceftriaxone and gentamicin for the treatment of febrile neutropenia. Arch. Dis. Child. 80: 125-131 [Abstract] [Full Text]  
  • Hammett-Stabler, C. A., Johns, T. (1998). Laboratory guidelines for monitoring of antimicrobial drugs. Clin. Chem. 44: 1129-1140 [Abstract] [Full Text]  
  • den Hollander, J. G., Mouton, J. W., Verbrugh, H. A. (1998). Use of Pharmacodynamic Parameters To Predict Efficacy of Combination Therapy by Using Fractional Inhibitory Concentration Kinetics. Antimicrob. Agents Chemother. 42: 744-748 [Abstract] [Full Text]  
  • den Hollander, J. G., Fuursted, K., Verbrugh, H. A., Mouton, J. W. (1998). Duration and Clinical Relevance of Postantibiotic Effect in Relation to the Dosing Interval. Antimicrob. Agents Chemother. 42: 749-754 [Abstract] [Full Text]  
  • (1997). Aminoglycosides once daily?. DTB 35: 36-37 [Abstract] [Full Text]  
  • Oliphant, C. M. (1997). Therapeutic Drug Monitoring of Therapy for Infectious Diseases. Journal of Pharmacy Practice 10: 7-19 [Abstract]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»